All In Biotech

NDA 016885 · Esteve

Lysodren

Mitotane · Oral

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Oct 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1970

Jul 8, 1970

Approved uses

1

Original approval plus efficacy supplements

Registered trials

17

5 Phase 3, 5 recruiting

FAERS reports

1,830

1,299 serious, 237 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK, SEVERE TRAUMA OR INFECTION Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death. If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. Monitor patients closely for infections and instruct patients to contact their physician immediately if injury, infection, or any other concomitant illness occurs [see Dosage and Administration (2.3) and Warnings and Precautions (5.1)]. WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK, SEVERE TRAUMA OR INFECTION See full prescribing information for complete boxed warning. Patients treated with LYSODREN are at increased risk for developing adrenal crisis in the setting of shock, severe trauma or infection that may lead to death. If...

What it is approved for

From the label in effect Mar 3, 2026.

LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). LYSODREN is an adrenal cytotoxic agent indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). ( 1 )

Mechanism: Mitotane is an adrenal cytotoxic agent with an unknown mechanism of action. Mitotane modifies the peripheral metabolism of steroids and directly suppresses the adrenal cortex. A reduction in 17-hydroxycorticosteroids in the absence of decreased corticosteroid levels and increased formation of 6-β-hydroxycortisol have been reported.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 8, 1970 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • LYSODREN · MITOTANE 500MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Mitotane" as an intervention, any sponsor and status, largest first.

All 17 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea319
  • off label use307
  • fatigue291
  • diarrhoea173
  • vomiting157
  • product dose omission issue142
  • adrenal insufficiency134
  • drug ineffective132
  • dizziness120
  • decreased appetite117
  • asthenia105
  • death88

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
20057
20068
200727
200826
200930
201018
201139
201258
201338
201421
201543
201641
201759
2018122
201955
202082
2021114
2022171
2023180
2024228
2025193
2026257

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lysodren (Mitotane)

2024 spending

$2.7M

Beneficiaries

194

1,120 claims

Per beneficiary

$13,698

$13.82 per unit

View as table
YearSpending
2020$1,576,483
2021$1,448,810
2022$1,960,773
2023$2,295,519
2024$2,657,364

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 57 on PubMed

Sponsor: Esteve

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.